Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)
Sponsor: National Cancer Institute (NCI)
Listed as NCT01802333, this PHASE3 trial focuses on Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .